Mads Daugaard

President at RAKOVINA THERAPEUTICS INC.

Net worth: 17 000 $ as of 2026-08-30

Finance

Consumer Services

Commercial Services

Profile

Mads Daugaard is the founder of VarCT Diagnostics ApS, founded in 2017, and Var2 Pharmaceutical, founded in 2012, where the title held is Chairman.
Current jobs include Chairman at Oncomal ApS, Associate Professor at the University of British Columbia, and President & Chief Scientific Officer at Rakovina Therapeutics, Inc. since 2021.
Former job includes Head-Molecular Pathology & Cell Imaging Unit at The Vancouver Prostate Centre.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
RAKOVINA THERAPEUTICS INC 0.59%	2026-09-15	125,000 ( 0.59% )	17 000 $	2026-08-30

Mads Daugaard active positions

Companies	Position	Start
RAKOVINA THERAPEUTICS INC.	President	2020-12-31
University of British Columbia University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University	Corporate Officer/Principal	-
Var2 Pharmaceutical	Founder	2011-12-31
VarCT Diagnostics ApS VarCT Diagnostics ApS VarCT Diagnostics ApS specializes in developing in vitro diagnostic assays for cancer detection and monitoring, focusing on the oncofetal chondroitin sulfate (ofcs) biomarker, which is re-expressed in most cancers but largely absent from healthy tissues except the placenta. The private company is based in Copenhagen, Denmark. The Danish company utilizes recombinant var2csa protein and proprietary high-affinity antibodies called vartumabs to detect ofcs with high sensitivity and specificity. The company's assays support early cancer detection, residual disease monitoring, and multi-cancer screening, including colorectal and bladder cancers, and they are developing immunohistochemistry companion diagnostics for tumor biopsies. VarCT Diagnostics is also advancing therapeutic applications using vartumabs-based platforms and plans a phase 0 microdosing clinical trial in 2024. The company maintains strategic collaborations with academic and industry partners internationally. The company was founded by Mads Daugaard.	Founder	2016-12-31
Oncomal ApS Oncomal ApS Financial ConglomeratesFinance Functions as a financial holding company	Chairman	-

All active positions of Mads Daugaard

Former positions of Mads Daugaard

Companies	Position	End
The Vancouver Prostate Centre The Vancouver Prostate Centre Miscellaneous Commercial ServicesCommercial Services Provides prostate cancer research, treatment, and education services	Corporate Officer/Principal	-

See the detail of Mads Daugaard's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mads Daugaard's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	6
University of British Columbia University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
The Vancouver Prostate Centre The Vancouver Prostate Centre Miscellaneous Commercial ServicesCommercial Services Provides prostate cancer research, treatment, and education services	Commercial Services
Rakovina Therapeutics, Inc. Rakovina Therapeutics, Inc. Financial ConglomeratesFinance Develops oncology therapeutics	Finance
Var2 Pharmaceutical
Oncomal ApS Oncomal ApS Financial ConglomeratesFinance Functions as a financial holding company	Finance
VarCT Diagnostics ApS VarCT Diagnostics ApS VarCT Diagnostics ApS specializes in developing in vitro diagnostic assays for cancer detection and monitoring, focusing on the oncofetal chondroitin sulfate (ofcs) biomarker, which is re-expressed in most cancers but largely absent from healthy tissues except the placenta. The private company is based in Copenhagen, Denmark. The Danish company utilizes recombinant var2csa protein and proprietary high-affinity antibodies called vartumabs to detect ofcs with high sensitivity and specificity. The company's assays support early cancer detection, residual disease monitoring, and multi-cancer screening, including colorectal and bladder cancers, and they are developing immunohistochemistry companion diagnostics for tumor biopsies. VarCT Diagnostics is also advancing therapeutic applications using vartumabs-based platforms and plans a phase 0 microdosing clinical trial in 2024. The company maintains strategic collaborations with academic and industry partners internationally. The company was founded by Mads Daugaard.